Roche's Sefaxersen Meets Primary Endpoint In Phase III IMAgINATION Study, Significantly Reduces Proteinuria Versus Placebo At 37 Weeks In IgA Nephropathy Patients
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potentialSefaxersen inhibits
Roche's new medicine worked better than a fake pill in testing. When a drug passes this big test, it means the company might have something valuable to sell.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.